Clinuvel's Scenesse Receives the US FDA's Approval for Erythropoietic Protoporphyria (EPP)
Shots:
- Scenesse (afamelanotide 16mg) is a drug developed for the treatment of rare genetic metabolic disorder and is approved to increase pain-free light exposure in adult patients with a history of phototoxic reactions from erythropoietic protoporphyria (EPP)
- In 2018- Scenesse also received European Medicines Agency’s as an orphan medicinal product- approval for EPP and is administered as a 16mg controlled-release injectable implant- designed for up to 60 days
- Scenesse (afamelanotide- 16mg) is a drug targeted for binding to melanocortin-1 receptor on skin cells and the results of P-III study has been published in the New England Journal of Medicine
Click here to read full press release/ article | Ref: PRNewswire | Image: Twitter
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
